Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 4;49(11):3692–3704. doi: 10.1007/s00259-022-05807-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Fibrin binding (in vitro) assay. First panel (a) illustrates the experimental setup using 3D-printed multi-well plates (fitted to the phased array coil). Fbn, fibrinogen; Thr, thrombin. Arrangement as shown in panel b: top left, Fbn + /Thr + ; top right, Fbn + /Thr-; bottom left, saline (control); bottom right, twofold higher concentration (control). Panel b shows a representative binding experiment with EP2104-R (25 µM) and gadobutrol (100 µM): In contrast to EP2104-R, which presented a substantial local decrease in longitudinal relaxation time for wells with fibrinogen and pre-activated thrombin, suggestive for strong binding to the fibrin pellet, gadobutrol exhibits no particular enhancement pattern. Third panel (c) shows substantial difference in ∆T1 (determined from respective Fbn + /Thr + and Fbn + /Thr- samples) between EP2104-R and gadobutrol (p = 0.009, n = 3, independent samples t-test, E2.2). M ± SEM. In the unbound state, EP2104-R exhibits higher relaxivity due to internal motion of the chelate complex. p-value < .05 was considered statistically significant. **p-value < 0.01